Evaxion Biotech A/S — Form 6-K Summary
Reporting period: January 2024; filed January 12, 2024. The filing reports corporate financing, warrant exercises, amended share capital authorizations, and resolutions of the January 11, 2024 extraordinary general meeting. Evaxion is a Danish foreign private issuer whose ADSs represent its ordinary shares.
Key Financing and Capitalization Matters
- Private placement: The previously announced private placement involved 9,726,898 ordinary shares represented by ADSs at a purchase price of $0.544 per share, together with warrants to purchase up to 9,726,898 additional ordinary shares.
- The warrants were immediately exercisable, expire three years after the closing date, and have an exercise price of $0.707 per ordinary share.
- The December 21, 2023 share issuance increased nominal share capital by DKK 9,726,898 to DKK 37,897,780.
- Warrant exercises: Exercises during a window that closed January 8, 2024 resulted in the issuance of 9,216 ordinary shares for aggregate cash consideration of DKK 9,216, approximately $1,350 based on the January 3, 2024 exchange rate. Nominal share capital increased to DKK 37,906,996.
- The filing does not provide revenue, profit or loss, operating cash flow, cash balance, debt balance, liquidity runway, or margin information.
Extraordinary General Meeting
At the January 11, 2024 meeting, 6,134,859 ordinary shares, representing 16.18% of shares outstanding at the meeting date, were voted. All submitted proposals were adopted with the required majority.
- The board’s authorization, effective until January 3, 2026, to issue warrants to directors, executive management, employees, advisers and consultants was increased to cover up to DKK 1,000,000 of nominal share capital.
- The board’s authorization, effective until May 1, 2027, to issue warrants to investors, lenders, consultants and advisers was increased to cover up to DKK 47,000,000 of nominal share capital. Warrants are to be issued at no less than market price at issuance.
- The authorization to issue new shares without pre-emptive rights was increased to cover up to DKK 47,000,000 of nominal share capital through cash contributions. Shares may be issued at market price or at a discount to the listed ADS price.
- The authorization to issue new shares with pre-emptive rights was increased to cover up to DKK 11,000,000 of nominal share capital through cash contributions.
- The board reported that, as of July 15, 2023, the company had lost more than half of its subscribed share capital under the Danish Companies Act. Management informed shareholders of the ongoing process to re-establish the company’s share capital.
Material Changes and Investor Considerations
- The company’s share capital increased through the private placement and subsequent warrant exercises.
- The expanded warrant and equity issuance authorities provide substantial potential capacity for future dilution and capital raising without, in some cases, pre-emptive rights for existing shareholders.
- Members of management and the board, as well as MSD GHI, a subsidiary of Merck, were among the investors in the private placement.
- The filing contains no new operating guidance, revenue outlook, profitability forecast, liquidity forecast, or detailed discussion of clinical, regulatory, or commercial developments.
Important Facts to Verify
- Whether the private placement proceeds and warrant terms were fully closed and issued as described in the referenced December 2023 filing.
- The company’s latest cash balance, cash burn, debt obligations, and expected liquidity runway.
- The status and terms of the plan to re-establish lost share capital.
- The number of outstanding shares and ADSs after the private placement and January warrant exercises.
- The potential dilution from the authorized warrants and future share issuances, including the DKK 47,000,000 non-pre-emptive issuance authorization.
- Any subsequent financing, clinical, regulatory, or business updates filed after January 12, 2024.